RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Zhang, Chun Ye ^a   Zhao, Yang Xing ^b   Xia, Rong Hui ^a   Han, Jing ^a   Wang, Bing Shun ^c   Tian, Zhen ^a   Wang, Li Zhen ^a   Hu, Yu Hua ^a   Li, Jiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b School of Medicine   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TUMOR MARKER; RASSF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADENOID CYSTIC CARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHINESE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; MIDDLE AGED; OVERALL SURVIVAL; PROMOTER REGION; RASSF1A GENE; SALIVARY ADENOID CYSTIC CARCINOMA; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; GENETICS; KAPLAN MEIER METHOD; MORTALITY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SALIVARY GLAND TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; CARCINOMA, ADENOID CYSTIC; CHINA; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; SALIVARY GLAND NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84907807393     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110159     Document Type: Article

References (40)

1. Tian Z, Li L, Wang L, Hu Y, Li J (2009) Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 39: 235-242.
2. Li J, Wang BY, Nelson M, Li L, Hu Y, et al. (2004) Salivary adenocarcinoma, not otherwise specified: a collection of orphans. Arch Pathol Lab Med 128: 1385-1394.
3. Rapidis AD, Givalos N, Gakiopoulou H, Faratzis G, Stavrianos SD, et al. (2005) Adenoid cystic carcinoma of the head and neck. Clinicopathological analysis of 23 patients and review of the literature. Oral Oncol 41: 328-335.
4. Nascimento AG, Amaral AL, Prado LA, Kligerman J, Silveira TR (1986) Adenoid cystic carcinoma of salivary glands. A study of 61 cases with clinicopathologic correlation. Cancer 57: 312-319.
5. Spiro RH, Huvos AG, Strong EW (1979) Adenoid cystic carcinoma: factors influencing survival. Am J Surg 138: 579-583.
6. Zhang CY, Xia RH, Han J, Wang BS, Tian WD, et al. (2013) Adenoid cystic carcinoma of the head and neck: clinicopathologic analysis of 218 cases in a Chinese population. Oral Surg Oral Med Oral Pathol Oral Radiol 115: 368- 375.
7. Shen C, Xu T, Huang C, Hu C, He S (2012) Treatment outcomes and prognostic features in adenoid cystic carcinoma originated from the head and neck. Oral Oncol 48: 445-449.
8. Gondivkar SM, Gadbail AR, Chole R, Parikh RV(2011) Adenoid cystic carcinoma: a rare clinical entity and literature review. Oral Oncol 47: 231-236.
9. Li J, El-Naggar A, Mao L (2005) Promoter methylation of p16INK4a, RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 104: 771-776.
10. Karray-Chouayekh S, Trifa F, Khabir A, Boujelbane N, Sellami-Boudawara T, et al. (2010) Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients. J Cancer Res Clin Oncol 136: 203-210.
11. Dammann R, Li C, Yoon JH, Chin PL, Bates S, et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 25: 315-319.
12. Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, et al. (2001) The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A 98: 7504-7509.
13. Zhang CY, Mao L, Li L, Tian Z, Zhou XJ, et al. (2007) Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer 110: 87-95.
14. Agathanggelou A, Cooper WN, Latif F (2005) Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 65: 3497-3508.
15. Wang J, Wang B, Chen X, Bi J (2011) The prognostic value of RASSF1A promoter hypermethylation in non-small cell lung carcinoma: a systematic review and meta-analysis. Carcinogenesis 32: 411-416.
16. Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G, et al. (2010) Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin Cancer Res 16: 2418-2426.
17. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, et al. (2010) PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 126: 1630-1639.
18. Gobel G, Auer D, Gaugg I, Schneitter A, Lesche R, et al. (2011) Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat.
19. Jiang Y, Cui L, Chen WD, Shen SH, Ding LD (2012) The Prognostic Role of RASSF1A Promoter Methylation in Breast Cancer: A Meta-Analysis of Published Data. PLoS One 7: e36780.
20. Miranda E, Destro A, Malesci A, Balladore E, Bianchi P, et al. (2006) Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer 95: 1101-1107.
21. Oliveira C, Velho S, Domingo E, Preto A, Hofstra RM, et al. (2005) Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene 24: 7630-7634.
22. Choi CH, Lee KM, Choi JJ, Kim TJ, Kim WY, et al. (2007) Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett 255: 26-33.
23. Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, et al. (2003) Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer 105: 204-209.
24. Riquelme E, Tang M, Baez S, Diaz A, Pruyas M, et al. (2007) Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma. Cancer Lett 250: 100-106.
25. Pan ZG, Kashuba VI, Liu XQ, Shao JY, Zhang RH, et al. (2005) High frequency somatic mutations in RASSF1A in nasopharyngeal carcinoma. Cancer Biol Ther 4: 1116-1122.
26. Reed K, Poulin ML, Yan L, Parissenti AM (2010) Comparison of bisulfite sequencing PCR with pyrosequencing for measuring differences in DNA methylation. Anal Biochem 397: 96-106.
27. Ku JL, Jeon YK, Park JG (2011) Methylation-specific PCR. Methods Mol Biol 791: 23-32.
28. Licchesi JD, Herman JG (2009) Methylation-specific PCR. Methods Mol Biol 507: 305-323.
29. Warnecke PM, Stirzaker C, Song J, Grunau C, Melki JR, et al. (2002) Identification and resolution of artifacts in bisulfite sequencing. Methods 27: 101-107.
30. Grote HJ, Schmiemann V, Geddert H, Bocking A, Kappes R, et al. (2006) Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 108: 129-134.
31. Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, et al. (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 11: 2156-2162.
32. Yeo W, Wong WL, Wong N, Law BK, Tse GM, et al. (2005) High frequency of promoter hypermethylation of RASSF1A in tumorous and non-tumourous tissue of breast cancer. Pathology 37: 125-130.
33. Buhmeida A, Merdad A, Al-Maghrabi J, Al-Thobaiti F, Ata M, et al. (2011) RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res 31: 2975- 2981.
34. Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, et al. (2012) Ras Association Domain Family 1A: A Promising Prognostic Marker in Recurrent Nonmuscle Invasive Bladder Cancer. Clin Genitourin Cancer 10: 114-120.
35. Ohshima J, Haruta M, Fujiwara Y, Watanabe N, Arai Y, et al. (2012) Methylation of the RASSF1A promoter is predictive of poor outcome among patients with Wilms tumor. Pediatr Blood Cancer.
36. Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120: 3163-3172.
37. Lo KW, Kwong J, Hui AB, Chan SY, To KF, et al. (2001) High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 61: 3877-3881.
38. de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, et al. (2012) An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial. Clin Cancer Res 18: 2976-2986.
39. EI-Naggar A, Huvos A (2005) Adenoid cystic carcinoma. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organization Classification of Tumours. Pathology and genetics of Head and Neck Tumors. Lyon: IARC Press. pp. 221-222.
40. Ellis GL AP (2008).Tumors of the salivary glands. AFIP atlas of tumor pathology. Maryland:ARP Press.36 p.